Comprehensive insight on the various healthcare team members a hematologist-oncologist may work with to optimize care of myeloproliferative neoplasms.
Pelabresib Combo Leads to Outcomes Linked to Better Survival in Myelofibrosis
Pelabresib plus Jakafi led to a reduction in spleen size and was tolerable in patients with myelofibrosis, according to data from MANIFEST-2.
Read More
FDA Stops Lung Cancer Trial, CAR-T Cell Therapy Is Cost Effective, Novel Drug Slows Fibrosis
The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.
Listen
New Drug May Decrease Need for Blood Draws in Patients With PV
Treatment with rusfertide led to a decrease in the need for blood draws and decreased levels of red blood cells in patients with polycythemia vera.
LeVar Burton Helping the MPN Community Through Advocacy and Storytelling
On this episode of the “Cancer Horizons” podcast, LeVar Burton sits down with CURE® to talk about the importance of MPN awareness and the power of storytelling in advocacy.
Community Helped a Patient When Their MPN Treatment Was Delayed
Thomas Silver discusses how a community of support helped a patient when his bone marrow transplant was delayed.
What is Cytoreduction in MPNs?
Dr. Douglas Tremblay of the Ichan School of Medicine explains the necessity of cytoreductive therapy for patients with MPNs such as essential thrombocythemia and polycythemia vera.